Senseonics Partners with Beta Bionics to Integrate Eversense 365 with iLet Bionic Pancreas
Event summary
- Senseonics and Beta Bionics are integrating Eversense 365 CGM with iLet Bionic Pancreas for automated insulin delivery.
- Commercial launch of the integrated system is planned for Q4 2026.
- Eversense 365 offers year-long implantable glucose monitoring, reducing device burden for diabetes management.
- The partnership aims to provide a differentiated AID experience without requiring carb counting.
The big picture
The partnership between Senseonics and Beta Bionics underscores the growing trend of integrating continuous glucose monitoring with automated insulin delivery systems to simplify diabetes management. This collaboration positions Senseonics to compete more effectively in the AID market, leveraging its unique implantable CGM technology. The success of this integration could set a precedent for future partnerships in the diabetes technology space.
What we're watching
- Market Expansion
- How the integration will expand Senseonics' reach within the automated insulin delivery market.
- Regulatory Approval
- The pace at which the integrated system secures necessary regulatory clearances for commercial launch.
- Competitive Dynamics
- Whether the partnership can differentiate Senseonics' offering from existing AID solutions.
Related topics